Heiligenstein J H, Tollefson G D, Faries D E
Psychopharmacology Division, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
J Affect Disord. 1994 Mar;30(3):163-73. doi: 10.1016/0165-0327(94)90077-9.
Fluoxetine (20 mg/day) and placebo were compared in 89 outpatient men and women with major depression with (n = 52) or without (n = 37) DSM-III-R melancholia in an 8-week double-blind study to determine predictors of treatment response. Fluoxetine was statistically superior to placebo both within the melancholic subtype and in the total patient group (all measures). Response rate and mean decrease in 17-item Hamilton Depression Rating Scale total score approached statistical significance in favor of fluoxetine-treated melancholic patients compared with fluoxetine-treated non-melancholic patients. There were no statistically significant differences between fluoxetine-treated and placebo-treated non-melancholic patients. Results support DSM-III-R melancholia as a predictor of antidepressant response.
在一项为期8周的双盲研究中，对89名患有重度抑郁症的门诊男女患者（其中52名符合《精神疾病诊断与统计手册》第三版修订版（DSM-III-R）中忧郁症标准，37名不符合）比较了氟西汀（20毫克/天）和安慰剂，以确定治疗反应的预测因素。在忧郁症亚型组和整个患者组中（所有测量指标），氟西汀在统计学上均优于安慰剂。与接受氟西汀治疗的非忧郁症患者相比，接受氟西汀治疗的忧郁症患者的缓解率和17项汉密尔顿抑郁量表总分的平均降低幅度接近统计学显著性，支持氟西汀治疗。接受氟西汀治疗的非忧郁症患者与接受安慰剂治疗的非忧郁症患者之间无统计学显著差异。结果支持将DSM-III-R忧郁症作为抗抑郁反应的预测指标。
